Guangzhou, Beijing, China:
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) introduced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic medication focusing on intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to uncover absolutely human antibody sequences that can be additional developed utilizing FineImmune’s distinctive cell remedy platform.
Biocytogen’s TCR-mimic antibody growth platform makes use of its proprietary absolutely human antibody RenMice™ (RenMab™ and RenLite® mice) which were additional engineered to categorical a human leukocyte antigen (HLA) gene. Antibodies towards intracellular tumor-associated antigens are subjected to superior high-throughput antibody screening applied sciences to uncover antibodies with excessive specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” mentioned Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell remedy firm, and has solved a number of vital boundaries within the microenvironment of strong tumors through the use of a number of proprietary expertise platforms, similar to GSOP for T-cell engineering, HAP for TCR identification, CMP for personalised TCR-T cell manufacturing and in vivo T-cell supply platform (TDP). FineImmune’s product pipelines embody TCR-T, CAR-T, TAL, TIL, and many others. The firm developed the primary personalised neoantigen-specific TCR-T cell remedy, which is in part I scientific trial now. In addition, FineImmune possesses applied sciences for the precision prediction of the efficacy and unwanted effects of immunotherapy, enabling healthcare professionals to present efficient and protected immunotherapy to sufferers with frequent malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” mentioned Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform makes use of HLA-expressing absolutely human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform goals to swiftly determine TCR-mimic antibodies with increased specificity and affinity than endogenous TCRs derived from sufferers. Currently, antibody sequences towards a number of intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the event of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a worldwide biotechnology firm that drives the analysis and growth of novel antibody-based medication with modern applied sciences. Using its proprietary RenMab™ /RenLite® mice platforms for absolutely human monoclonal and bispecific antibody growth, Biocytogen has built-in its in vivo drug efficacy screening platforms and robust scientific growth experience to streamline all the drug growth course of. Biocytogen is endeavor a large-scale challenge to develop antibody medication for greater than 1000 targets, often known as Project Integrum, and has entered ongoing collaborations with dozens of companions worldwide to produce a wide range of first-in-class and/or best-in-class antibody medication. The firm’s pipeline contains 12 core merchandise, amongst which two merchandise are in part II multi-regional scientific trials and two merchandise are in part I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the inventory code: 02315.HK. For extra data, please go to http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation pushed firm primarily based in China. The firm is especially engaged within the growth of strong tumor immunotherapy medication and associated companies. It has solved key technical bottlenecks in strong tumor immunotherapy and possesses core applied sciences. Plenty of T-cell remedy merchandise for strong tumors are in scientific trials, in addition to diagnostic reagents for correct identification of efficient populations. It has a 2000 sq. meter immunotherapy R&D laboratory and a GMP manufacturing workshop for cell remedy merchandise in Guangzhou Science City. The firm’s individualized TCR-T cell remedy product (new drug) has been carried out scientific analysis within the Affiliated Tumor Hospital of Sun Yat sen University. At current, greater than 20 immune cell remedy merchandise and applied sciences are below analysis and growth. For extra data, please go to http://www.fineimmu.com/.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220914005630/en/
